Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
September 08 2020 - 8:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a
pharmaceutical technology company, today announced that Robert F.
Apple, President and Chief Executive Officer, is scheduled to
present at the H.C. Wainwright 22nd Annual Global Virtual
Investment Conference.
Details of the presentation are as follows:
Event: |
H.C.
Wainwright 22nd Annual Global Virtual Investment Conference |
Format: |
Fireside Chat and 1x1 Meetings |
Fireside Chat Date: |
Monday, September 14, 2020 |
Fireside Chat Time: |
1:30pm ET |
A live webcast of the fireside chat will be available under the
“For Investors” section of the Antares Pharma website at
www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a pharmaceutical technology company
focused primarily on the development and commercialization of
self-administered injectable pharmaceutical products using advanced
drug delivery auto injector technology. The Company has a portfolio
of proprietary and partnered commercial products with several
product candidates in various stages of development, as well as
significant strategic alliances with industry leading
pharmaceutical companies including Teva Pharmaceutical Industries,
Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc.
(Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares
Pharma’s FDA approved products include XYOSTED® (testosterone
enanthate) injection, OTREXUP® (methotrexate) injection for
subcutaneous use and Sumatriptan Injection USP, which is
distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995
This press release contains forward-looking statements
within the meaning of the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are subject to certain risks and uncertainties that can
cause actual results to differ materially from those
described. Factors that may cause such differences include,
but are not limited to: the uncertainty regarding the duration,
scope and severity of the COVID-19 pandemic and the mitigation
measures and other restrictions implemented in response to the same
and the impact on reinstated 2020 full-year revenue guidance,
demand for our products, new patients and prescriptions, future
revenue, product supply, and our overall business, operating
results and financial condition; market acceptance, adequate
reimbursement coverage and commercial success of XYOSTED® and
future revenue from the same; market acceptance of Teva’s generic
epinephrine auto-injector product and future revenue from the same;
our expectations regarding whether the FDA will pursue withdrawal
of approval for AMAG Pharmaceuticals Inc.’s Makena® subcutaneous
auto injector following the recent FDA advisory committee meeting
and future prescriptions, market acceptance and revenue from
Makena® subcutaneous auto injector; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; continued growth of prescriptions and sales
of OTREXUP®; the timing and results of the Company’s or its
partners’ research projects or clinical trials of product
candidates in development including Idorsia Pharmaceuticals, Pfizer
and Teva; actions by the FDA or other regulatory agencies
with respect to the Company’s products or product candidates of its
partners; continued growth in product, development, licensing and
royalty revenue; the Company’s ability to meet loan extension and
interest only payment milestones and the ability to repay the debt
obligation to Hercules Capital; the Company’s ability to
obtain financial and other resources for its research, development,
clinical, and commercial activities and other statements regarding
matters that are not historical facts, and involve predictions.
These statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance,
achievements or prospects to be materially different from any
future results, performance, achievements or prospects expressed in
or implied by such forward-looking statements. In some cases you
can identify forward-looking statements by terminology such as
''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'',
''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:Tram BuiVice President, Corporate
Communications and Investor
Relations609-359-3020tbui@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Apr 2023 to Apr 2024